{"id":"W3169437264","doi":"10.1200/jco.2021.39.15_suppl.1001","title":"Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Hazard ratio; Fulvestrant; Internal medicine; Breast cancer; Placebo; Oncology; Cancer; Nuclear medicine; Surgery; Confidence interval; Estrogen receptor; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004103205,0.0008850726,0.001269566,0.0003641204,0.0002035385,0.0008262092,0.0006151192,0.0006067554,0.003143892],"category_scores_gemma":[0.002285712,0.0002286344,0.001575748,0.0004636773,0.0003072344,0.0005225118,0.0005133119,0.001483407,0.0004609661],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005331783,"about_ca_system_score_gemma":0.0005805799,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006538897,"about_ca_topic_score_gemma":0.002206703,"domain_scores_codex":[0.9989568,0.0006346016,0.0000598098,0.0001204126,0.0001274438,0.0001010226],"domain_scores_gemma":[0.9985272,0.0004424063,0.0005002783,0.0001456462,0.00008119267,0.0003033056],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8767881,0.003315946,0.03117608,0.00173704,0.007572887,0.0001378876,0.0001710108,0.003826153,0.005986992,0.0003067318,0.00831286,0.06066832],"study_design_scores_gemma":[0.3753696,0.2168077,0.3555228,0.0003402935,0.02125105,0.0006789215,0.0001535242,0.004982439,0.004195979,0.001032401,0.01955188,0.0001135185],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9697341,0.006696229,0.0008091685,0.0004672455,0.000121962,0.0009491636,0.01687503,0.0001074274,0.004239732],"genre_scores_gemma":[0.9684827,0.001889526,0.0008158439,0.0005699638,0.0001617468,0.001483766,0.02406875,0.00003544074,0.002492268],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004103205,"threshold_uncertainty_score":0.02170002,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05298804300520032,"score_gpt":0.4116209007185532,"score_spread":0.3586328577133529,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}